0083> Methods of Treating Metastatic Breast Canc

0083] Methods of Treating Metastatic Breast Cancer and Solid Tumors

0086] "..... In a further embodiment, the CCR5 binding agent comprises the monoclonal antibody PA14, leronlimab, or CCR5mAb004, or a binding fragment thereof."

CCR5mAb004 is Human Genome Sciences:

* (HGS) was a biopharmaceutical company founded by Craig Venter in 1992 that focused on developing drugs based on the human DNA sequence, primarily researching treatments for diseases like hepatitis C, systemic lupus erythematosus, anthrax, and cancer; it was eventually acquired by GlaxoSmithKline (GSK) in 2012 and ceased operations as a separate entity following the acquisition.

GSK scorecard:
1. Late 2022 we hired their retired bio-statitian.

2. Max joined us from their ViiV controlled company.

3. They own 1 of the 2 FcRn mutations LL uses for stability.

4. This HGS mention in our cancer patent.

& 6 years before GSK bought HGS:
Dr. J has been getting around for a while;

https://www.aidsmap.com/news/sep-2006/antibod...tudy-shows

Dr. J:
Oncology – December 2024 Update.

The Company will be prioritizing oncology in 2025, as we believe this indication holds the potential for the highest value return to the Company in the form of a significant partnership and/or drug approval.

I think it's all working up to a:

BOOOM !$!$!$! ...for shareholders